147 SCLC Clinical Trials Recruiting Now (May 2026): Small Cell Lung Cancer — Tarlatamab, DLL3 BiTEs, B7-H3 ADCs, I-DXd, Lurbinectedin

Last updated: May 25, 2026

🔔 Pre-ASCO 2026 (May 29 – June 2) update: SCLC is now an unusually crowded ADC field. Three distinct target classes have reached Phase 3 simultaneously: DLL3 (tarlatamab BiTE FDA-approved 2L+ → testing 1L combination in NCT07005128; /drugs/tarlatamab; obrixtamig and ZG006 entering trials), B7-H3 ADCs (ifinatamab deruxtecan / I-DXd Phase 3 in NCT06203210; HS-20093 ARTEMIS-008; MHB088C; YL201), and TROP2 ADC (sacituzumab govitecan vs SOC in pretreated ES-SCLC, NCT06801834). DeLLphi-303/305 tarlatamab combination data and ADC head-to-heads are anticipated ASCO 2026 topics.

Current Clinical Trial Landscape

Active research areas in 2026:

Standard of care: Limited-stage: concurrent chemoRT (cisplatin/etoposide + RT) ± PCI; durvalumab consolidation after chemoRT is emerging as a new option per Phase 3 data. Extensive-stage 1L: platinum/etoposide + atezolizumab or durvalumab. Second-line (2L+): tarlatamab (DLL3-targeting BiTE, FDA-approved May 2024 per DeLLphi-301), lurbinectedin, or topotecan.

Recruiting Trials by Treatment Setting

Limited-Stage SCLC

Standard is concurrent chemoradiation ± PCI. Active Phase 3 trials test consolidation immunotherapy and refined radiation strategies:

Extensive-Stage SCLC — First-Line

Platinum/etoposide + checkpoint immunotherapy is standard. The major new direction is layering tarlatamab onto the chemo-IO backbone (DeLLphi-303 / -305 program):

Extensive-Stage — Second-Line and Beyond (Relapsed/Refractory)

After 1L progression, tarlatamab and lurbinectedin are established options. The post-tarlatamab/post-lurbinectedin landscape is now crowded with three distinct ADC target classes (DLL3, B7-H3, TROP2) and next-gen DLL3 agents:

Brain Metastases (SCLC-specific)

Brain mets are common in SCLC (up to 60% over disease course). Active Phase 3 trials refine radiation strategies — moving from whole-brain to targeted approaches:

Showing selected notable trials. View all 147 recruiting SCLC interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find small cell lung cancer clinical trials I'm eligible for?

Enter your SCLC details into ClinTrialFinder — including limited vs extensive stage, prior treatments, and brain metastasis status. The AI matches you with trials based on your specific profile in minutes.

What SCLC trials are currently recruiting?

There are 147 recruiting interventional trials for SCLC as of May 2026 (NSCLC-exclusion filter applied). Highlights include tarlatamab (DLL3 BiTE, FDA-approved 2L+, now in 1L combination Phase 3 with carbo/etoposide + durvalumab), next-generation DLL3 agents (obrixtamig BiTE DAREON-Lung-1, ZG006 trispecific, ZL-1310 ADC), B7-H3 ADCs (ifinatamab deruxtecan / I-DXd, HS-20093 ARTEMIS-008, MHB088C, YL201), TROP2 ADC (sacituzumab govitecan vs SOC in pretreated ES-SCLC), lurbinectedin combinations (vs topotecan), ivonescimab (AK112 PD-1/VEGF bispecific) consolidation for LS-SCLC, and consolidation immunotherapy after chemoradiation (durvalumab, sugemalimab, toripalimab + tifcemalimab).

Are B7-H3 ADCs the next major class for SCLC after tarlatamab?

B7-H3 (CD276) is highly expressed on SCLC and several B7-H3-directed ADCs have entered Phase 3 simultaneously: ifinatamab deruxtecan (I-DXd, NCT06203210), HS-20093 (ARTEMIS-008), MHB088C, and YL201 are all testing against treatment-of-physician's-choice or topotecan in relapsed SCLC. Head-to-head readouts will determine relative efficacy and the post-tarlatamab/post-lurbinectedin landscape. ASCO 2026 is expected to include updated B7-H3 ADC data.

What's new in the 1L extensive-stage SCLC setting?

The major new direction is layering tarlatamab onto the chemo-immunotherapy backbone. NCT07005128 (DeLLphi 1L combination) compares tarlatamab + durvalumab + carboplatin + etoposide vs durvalumab + carbo/etop — the registrational 1L combination study. Other 1L novel additions include BNT327 (PD-L1/VEGF bispecific) + chemotherapy (NCT06712355) and BMS-986489 (BMS-986012 fucosyl-GM1 mAb + nivolumab fixed-dose, NCT06646276).

Find SCLC Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials

Related Disease Trials

Lung Cancer (NSCLC) Trials Mesothelioma Trials Head and Neck Cancer Trials All Disease Trials

Related Drug Trials

Tarlatamab (Imdelltra, AMG 757) Ivonescimab (AK112, PD-1/VEGF bispecific) All Drug Trials

Learn More

What Information Do You Need for a Clinical Trial Search? How We Rank Trials: Evidence-Informed Scoring Our Guided Questionnaire: Answer Questions, Find Trials

This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.